克隆氏症市场：KOL 洞察

本报告探讨了目前和新兴的克隆氏症治疗方法，包括 TNF 抑制剂、Entyvio、Stelara、Skyrizi、Rinvoq、Tremfya、Omvoh、Zeposia 和 Velsipity。对这些治疗的功效、安全性和实用性进行了深入分析，并对可能影响未来处方趋势的近期临床试验进行了深入分析。研究了生物相似药和皮下製剂对市场的影响，并深入研究中度至重度克隆氏症的治疗前景如何演变。

目录

执行摘要

研究目的

• 已上市药品
  • TNF 抑制剂 (Remicade, Humira, Cimzia)
  • Entyvio (vedolizumab; Takeda)
  • Stelara (ustekinumab; Johnson & Johnson)
  • Skyrizi (risankizumab; AbbVie)
  • Rinvoq (upadacitinib; AbbVie)
• 研究药物
  • Tremfya (guselkumab; Johnson & Johnson Biotech)
  • Omvoh (mirikizumab; Lilly)
  • Zeposia (ozanimod; Bristol Myers Squibb)
  • Velsipity (etrasimod; Pfizer)

未来治疗趋势

• 克隆氏症的未来治疗策略可能倾向于合併治疗、IL-23 抑制剂和口服治疗
  • FMT 在 CD 中具有潜在的应用，但该策略很复杂且迄今为止尚未得到证实

附录

Explore current and emerging treatments for Crohn's disease, including TNF inhibitors, Entyvio, Stelara, Skyrizi, Rinvoq, Tremfya, Omvoh, Zeposia, and Velsipity. This comprehensive report offers an in-depth analysis of the efficacy, safety, and usability of these treatments, as well as insights into recent clinical trials that could shape future prescribing trends. Examine the impact of biosimilars and subcutaneous formulations on the market, offering a detailed look at how the treatment landscape for moderate-to-severe Crohn's disease is evolving. Gain valuable knowledge on physician and payer preferences, the competitive positioning of pipeline products, and the overall market trends influencing drug therapies for Crohn's disease.

Key brands covered in this report:

• Remicade (infliximab)
• Humira (adalimumab)
• Cimzia (certolizumab pegol)
• Entyvio (vedolizumab)
• Stelara (ustekinumab)
• Skyrizi (risankizumab)
• Rinvoq (upadacitinib)
• Tremfya (guselkumab)
• Omvoh (mirikizumab)
• Zeposia (ozanimod)
• Velsipity (etrasimod)

Key questions answered:

• Which CD therapies are preferred for different patient segments and lines of therapy?
• How do medical professionals perceive the efficacy, tolerability, and ease of administration of these therapies?
• Which recent clinical trials could significantly influence CD prescribing trends?
• How might the use of current and pipeline drugs change in the future?
• What must pipeline products demonstrate to compete with existing CD therapies?
• Which pipeline products are most promising and how might they impact the market?
• How will the CD treatment landscape evolve for different patient segments and therapy lines?

Companies:

AbbVie, Lilly, AstraZeneca, UCB, Pfizer, Merck Sharp & Dohme, Bristol Myers Squibb, Takeda, Johnson & Johnson.

Table of Contents

Executive summary

Research objectives

• Marketed drugs
  • TNF inhibitors (Remicade, Humira, Cimzia)
  • Entyvio (vedolizumab; Takeda)
  • Stelara (ustekinumab; Johnson & Johnson)
  • Skyrizi (risankizumab; AbbVie)
  • Rinvoq (upadacitinib; AbbVie)
• Pipeline drugs
  • Tremfya (guselkumab; Johnson & Johnson Biotech)
  • Omvoh (mirikizumab; Lilly)
  • Zeposia (ozanimod; Bristol Myers Squibb)
  • Velsipity (etrasimod; Pfizer)

Future treatment trends

• Future treatment strategies for Crohn's could favour combinations, IL-23 inhibitors and oral therapies
  • FMT could have some applications in CD, but the strategy is complex and, to date, unproven

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe